


## Content in this document:

Several users share their experience of the novel, validated biomarker.

## Online Content:

[Prof. Dr Tascini discusses improved patient assessment with MR-proADM](#)



HealthManagement, Volume 20 - Issue 6, 2020

Improved Patient Assessment with MR-proADM

## Webinar:

[Learn about the results of the interventional trial IDEAL and how MR-proADM can improve discharge decisions](#)



Improving discharge in the ED: identifying patients with suspicion of infection in the ED who have low disease severity using MR-proADM

Juan González del Castillo, Hospital Clínico San Carlos, Madrid, Spain

## MR-proADM can help improve management of COVID-19 patients

COVID-19 has delivered an enormous challenge to healthcare providers. Physicians have been forced to make difficult decisions around how to best provide patient care at a time when resources are most stretched. To help improve risk stratification, several hospitals have implemented Thermo Scientific™ B·R·A·H·M·S™ MR-proADM KRYPTOR™ test into their clinical routine to improve assessment of disease severity and progression. In this document, several users share their experience of the novel, validated biomarker.



**Dr. Juan Gonzalez del Castillo**  
**Hospital Clinico San Carlos, Madrid, Spain, Emergency Department, 861 beds**

The hospital implemented MR-proADM in 2020 in the ED.

*“MR-proADM identifies high risk patients, even those with low NEWS and SOFA scores. Therefore, it is a very good risk stratification biomarker and accurately identifies low risk and high-risk infectious patients and therefore **prevents unnecessary hospitalizations**. This was successfully proven in a recently finished interventional study.*


*In the current SARS-CoV2 pandemic, as well as in usual clinical practice, stratification of patients according to their risk to progress to more severe disease state and assignment to the required level of care as outpatient, hospital or ICU care is of utmost importance.”*

**Dr. Jacopo M. Legramante**  
**Policlinico Tor Vergata, Rome Italy, Emergency Department, 400 beds**

The Hospital successfully implemented MR-proADM before the outbreak of the COVID-19. Based on Legramante's experience<sup>1</sup> the MR-proADM test together with CURB score could help rule out patients with pulmonary problems. In the current situation, MR-proADM is monitored once per day in the ICU to evaluate progression/regression of the coronavirus disease.



*“Our preliminary data show that MR-proADM seems to represent the most powerful biomarker predicting death, especially in critically ill patients affected by COVID-19 related pneumonia, where the fatal outcome can happen earlier (suddenly), within a week. It seems particularly useful in **risk stratification of patients affected by the new syndrome named “viral sepsis”**, which characterizes patients affected by SARS-CoV-2.”*



**Dr. Iolanda Jordan**

**Hospital Sant Joan de Deu, Barcelona, Spain, pediatric ICU, 401 beds**

The Hospital started regular use of MR-proADM in January 2020. MR-proADM is used as a prognostic marker in cardiac, sepsis, severe respiratory cases and lately also COVID-19 patients.

*"MR-proADM has a great value in the acute phase of the decompensated patient. Its main strength is **its prognostic value**. MR-proADM also seems to have a relevant value in multisystemic inflammatory syndrome in pediatric patients (MIS-C)."*

**Dr. Luigi Atripaldi and Dr. Silvia Leonardi**

**AZIENDA OSPEDALIERA DEI COLLI Monaldi-Cotugno-CTO, Immunochemistry Lab, Naples, Italy, 682 beds**

Dr. Atripaldi and Dr. Leonardi started using MR-proADM in COVID-19 patients admitted to resuscitation and ICU. It is used mainly in **patients treated with anti-interleukin 6 antibody therapy**.

MR-proADM is measured every 24 hours to evaluate the trend of the analyte and relate it to the patient's clinical status.

*"MR-proADM has been very **useful in the monitoring of ICU patients** but also in patients suffering from various infectious diseases. The use of MR-proADM in monitoring patients affected by COVID-19 has just been introduced so we still have to evaluate its diagnostic or prognostic value."*



**References:**

1. Legramante, J.M., et al., *Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB*. PLoS One, 2017. 12(11): p. e0187702.

**Clinical Diagnostics**

Thermo Fisher Scientific  
B·R·A·H·M·S GmbH  
Neuendorfstr. 25  
16761 Hennigsdorf  
Deutschland

+49 (0)3302 883 0  
+49 (0)3302 883 100 Fax  
info.brahms@thermofisher.com  
www.thermoscientific.com/brahms



Find out more at [thermoscientific.com/proadrenomedullin](https://www.thermoscientific.com/proadrenomedullin)

Product is CE marked but not 510(k)-cleared and not [yet] available for sale in the U.S. Availability of product in each country depends on local regulatory marketing authorization status.

© 2020 Thermo Fisher Scientific Inc. All rights reserved.

All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. KRYPTOR is a trademark of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Specifications, terms and pricing are subject to change.